Regeneron Announces the 2024 Winners of the Regeneron Prize for Creative Innovation
31 Juillet 2024 - 1:30PM
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced
the winners of the 12th annual Regeneron Prize for Creative
Innovation (the Regeneron Prize), an award that recognizes,
celebrates and rewards outstanding talent and creativity from
early-career scientists in biomedical research.
Each year, Regeneron asks leading research universities across
the United States to nominate their top graduate students and
postdoctoral fellows, who are then invited to conceptualize and
propose "dream projects" within the realm of biomedical science.
The finalists present their proposals to a selection committee
comprised of Regeneron’s leading scientists who evaluate the
projects based on scientific merit, creativity and originality.
This year’s winners are Christopher Giuliano
and Julian Roessler, both Ph.D. candidates at the
Massachusetts Institute of Technology’s (MIT) Whitehead Institute
for Biomedical Research. Each has been awarded $50,000, in addition
to a $10,000 grant to their home institution to support its seminar
series. Six other finalists each received $5,000 awards.
“We launched the Regeneron Prize twelve years ago to help
encourage and reward ‘blue sky’ thinking in biomedicine,” said
George D. Yancopoulos, M.D., Ph.D., co-Founder, Board co-Chair,
President and Chief Scientific Officer of Regeneron. “Every amazing
medical breakthrough that exists today — from a vaccine for polio,
to a treatment for Ebola, to technologies that can edit genes
within a patient’s body — was once just a crazy idea. Society needs
more big ideas that could one day change lives, and these
remarkable students have impressed and inspired us with their
ability to think deeply, strategically and ambitiously.”
Christopher Giuliano, a Ph.D. candidate in
Biology at MIT, is working in the laboratory of Dr. Sebastian
Lourido at the Whitehead Institute. As an undergraduate,
Christopher simultaneously researched biochemistry in Dr. Steve
Glynn’s lab at State University of New York (SUNY) at Stony Brook
and cancer biology in Dr. Jason Sheltzer’s lab at Cold Spring
Harbor Laboratory in New York. Throughout his graduate career, he
has pursued an interest in infectious disease and immunology
studying the host response to Toxoplasma gondii, a parasite that
causes toxoplasmosis. Christopher aims to repurpose the parasite's
ability to manipulate muscle cells to improve the efficiency of
muscle-directed gene therapies. Christopher’s Regeneron Prize
winning proposal leveraged insights from his focused studies on
infectious agents to enhance broader therapeutic strategies, aiming
to revolutionize how we design treatments for complex diseases.
Julian Roessler, a Ph.D. candidate in Biology
at MIT, is working in the laboratory of Dr. Siniša Hrvatin from the
Whitehead Institute. Julian earned his BA in Biochemistry from the
University of Pennsylvania, where he was a Vagelos Molecular Life
Sciences Scholar. He completed a Master’s degree in Chemistry, also
from the University of Pennsylvania, studying the heat shock
response in ants with Dr. Shelley Berger. Since joining MIT, Julian
has worked with Dr. David Sabatini studying the mTORC1 pathway
before joining Dr. Hrvatin’s laboratory in 2021 to study the
hypothalamic basis of torpor, a hypometabolic state. His research
focuses on understanding the neurocircuitry and organ systems that
coordinate responses to environmental challenges. Julian’s
Regeneron Prize winning proposal applied ideas from his specialized
research areas to broader systems, with the goal of understanding
the brain circuitry required to deal with particular stressors to
human survival.
"Regeneron's Prize encourages early career scientists to work
independently to solve a problem that is important to them. We look
for originality and creativity on the one hand, and practicality on
the other," said David Glass, M.D., Vice President of Research
and Chair of the Postdoctoral Program at Regeneron.
A key focus of Regeneron’s social impact work is to inspire and
prepare young people to pursue STEM careers. As a company founded
and led by physician-scientists, Regeneron is committed to
fostering the next generation of scientific innovators who can help
solve society’s greatest challenges. Since its inception in 2013,
the Regeneron Prize has supported early-career scientists with more
than $1.7 million in awards. Additionally, since 2020, our STEM
efforts and partnerships have supported over 2.4 million students,
including through premier high school science competitions, such as
the Regeneron Science Talent Search (Regeneron STS) and the
Regeneron International Science & Engineering Fair (Regeneron
ISEF).
Requests for applications for the Regeneron Prize are
distributed to academic institutions each December. Regeneron asks
institutions to nominate two graduate students and two postdoctoral
fellows. In addition to the dream project proposals, submissions
must include a curriculum vitae and samples of publications that
enable the selection committee to review each nominee's scholarly
productivity. For more information, please
email science.education@regeneron.com.
About Regeneron Regeneron (NASDAQ:
REGN) is a leading biotechnology company that
invents, develops and commercializes life-transforming
medicines for people with serious diseases. Founded and led by
physician-scientists, our unique ability to repeatedly and
consistently translate science into medicine has led to
numerous approved treatments and product candidates in development,
most of which were homegrown in our laboratories. Our medicines and
pipeline are designed to help patients with eye diseases, allergic
and inflammatory diseases, cancer, cardiovascular and metabolic
diseases, neurological diseases, hematologic conditions,
infectious diseases, and rare diseases.
Regeneron believes that operating as a good corporate citizen is
crucial to delivering on our mission. We approach corporate
responsibility with three goals in mind: to improve the lives of
people with serious diseases, to foster a culture of integrity and
excellence and to build sustainable communities. Regeneron is proud
to be included on the Dow Jones Sustainability World Index and the
Civic 50 list of the most “community-minded” companies in the U.S.
Throughout the year, Regeneron empowers and supports employees to
give back through our volunteering, pro bono and matching gift
programs. Our most significant philanthropic commitments are in the
area of early science education, including the Regeneron Science
Talent Search (STS) and the Regeneron International Science and
Engineering Fair (ISEF).
For more information, please visit www.Regeneron.com or follow
Regeneron on LinkedIn, Instagram, Facebook or X.
Media Contacts: Joseph Brown,
Regeneron386-283-1323Joseph.Brown2@regeneron.com
Regeneron Pharmaceuticals (NASDAQ:REGN)
Graphique Historique de l'Action
De Août 2024 à Sept 2024
Regeneron Pharmaceuticals (NASDAQ:REGN)
Graphique Historique de l'Action
De Sept 2023 à Sept 2024